Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Radiation in PD-1 Resistant Head and Neck Cancer
NCT03085719Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jun 2017
- Primary completion
- Nov 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Progression-Free Survival at 1 year. Started Jun 2017; status: active, not recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03085719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03085719.